Localized-statistical quantification of human serum proteome associated with type 2 diabetes

PLoS ONE

Volumn 3, Issue 9, 2008, Pages

  Li, Rong Xia ^a   Chen, Hai Bing ^b   Tu, Kang ^a   Zhao, Shi Lin ^a   Zhou, Hu ^a   Li, Su Jun ^a   Dai, Jie ^a   Li, Qing Run ^a   Nie, Song ^a   Li, Yi Xue ^a   Jia, Wei Ping ^b   Zeng, Rong ^a   Wu, Jia Rui ^a,c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 GLOBIN; ALPHA GLOBIN; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C2; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CASEIN KINASE II; CASEIN KINASE II BETA; CERULOPLASMIN; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C8A; FICOLIN; FICOLIN 2; FICOLIN 3; HAPTOGLOBIN; HEMOPEXIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN MU CHAIN; KERATIN TYPE I; KERATIN TYPE II; PSORIASIN; RESERPINE; SERUM AMYLOID A; THROMBOCYTE FACTOR 4; THYROGLOBULIN ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LECTIN; PLASMA PROTEIN;

AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; MALE; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; QUANTITATIVE ANALYSIS; VALIDATION PROCESS; AGAR GEL ELECTROPHORESIS; BIOSYNTHESIS; BLOOD; CHEMISTRY; DISEASE COURSE; METABOLISM; METHODOLOGY; MIDDLE AGED; REPRODUCIBILITY; STATISTICAL MODEL;

AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ELECTROPHORESIS, AGAR GEL; HUMANS; LECTINS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROTEOMICS; REPRODUCIBILITY OF RESULTS;

EID: 52449124453     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003224     Document Type: Article

References (67)

1. Korc M (2003) Diabetes mellitus in the era of proteomics. Mol Cell Proteomics 2: 399-404.
2. Zimmet P (2003) The burden of type 2 diabetes: are we doing enough? Diabetes Metab 29: 6S9-18.
3. Horikawa Y, Yamasaki T, Nakajima H, Shingu R, Yoshiuchi I, et al. (2003) Identification of a novel variant in the phosphoenolpyruvate carboxykinase gene promoter in Japanese patients with type 2 diabetes. Horm Metab Res 35: 308-312.
4. Kim EY, Shin CH, Yang SW (2003) Polymorphisms of HLA class II predispose children and adolescents with type 1 diabetes mellitus to autoimmune thyroid disease. Autoimmunity 36: 177-181.
5. Vendrell J, Fernandez-Real JM, Gutierrez C, Zamora A, Simon I, et al. (2003) A polymorphism in the promoter of the tumor necrosis factor-alpha gene (-308) is associated with coronary heart disease in type 2 diabetic patients. Atherosclerosis 167: 257-264.
6. Lindgren CM, Widen E, Tuomi T, Li H, Almgren P, et al. (2002) Contribution of known and unknown susceptibility genes to early-onset diabetes in scandinavia: evidence for heterogeneity. Diabetes 51: 1609-1617.
7. Rao AA, Sridhar GR, Das UN (2007) Elevated butyrylcholinesterase and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Med Hypotheses.
8. Rao AA, Sridhar GR, Srinivas B, Das UN (2007) Bioinformatics analysis of functional protein sequences reveals a role for brain-derived neurotrophic factor in obesity and type 2 diabetes mellitus. Med Hypotheses.
9. On YK, Park HK, Hyon MS, Jeon ES (2007) Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 71: 868-873.
10. Scott EM, Carter AM, Findlay JB (2005) The application of proteomics to diabetes. Diab Vasc Dis Res 2: 54-60.
11. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. pp 845-867.
12. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, et al. (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353: 1649-1652.
13. Duncan BB, Schmidt MI, Offenbacher S, Wu KK, Savage PJ, et al. (1999) Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 22: 767-772.
14. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. Jama 286: 327-334.
15. Festa A, D'Agostino R Jr, Tracy RP, Haffner SM (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51: 1131-1137.
16. Peeters A, Beckers S, Verrijken A, Roevens P, Peeters P, et al. (2007) Variants in the FTO gene are associated with common obesity in the Belgian population. Mol Genet Metab.
17. Ye X, Yu Z, Li H, Franco OH, Liu Y, et al. (2007) Distributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese people. J Am Coll Cardiol 49: 1798-1805.
18. Nedelkov D, Kiernan UA, Niederkofler EE, Tubbs KA, Nelson RW (2005) Investigating diversity in human plasma proteins. Proc Natl Acad Sci U S A 102: 10852-10857.
19. Zhang R, Barker L, Pinchev D, Marshall J, Rasamoelisolo M, et al. (2004) Mining biomarkers in human sera using proteomic tools. Proteomics 4: 244-256.
20. Dayal B, Ertel NH (2002) ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res 1: 375-380.
21. Sundsten T, Eberhardson M, Goransson M, Bergsten P (2006) The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci 4: 22.
22. Georgiou HM, Rice GE, Baker MS (2001) Proteomic analysis of human plasma: failure of centrifugal ultrafiltration to remove albumin and other high molecular weight proteins. Proteomics 1: 1503-1506.
23. He P, He HZ, Dai J, Wang Y, Sheng QH, et al. (2005) The human plasma proteome: analysis of Chinese serum using shotgun strategy. Proteomics 5: 3442-3453.
24. Tu CJ, Dai J, Li SJ, Sheng QH, Deng WJ, et al. (2005) High-sensitivity analysis of human plasma proteome by immobilized isoelectric focusing fractionation coupled to mass spectrometry identification. J Proteome Res 4: 1265-1273.
25. Jin WH, Dai J, Li SJ, Xia QC, Zou HF, et al. (2005) Human plasma proteome analysis by multidimensional chromatography prefractionation and linear ion trap mass spectrometry identification. J Proteome Res 4: 613-619.
26. Koopman RJ, Mainous AG 3rd, Diaz VA, Geesey ME (2005) Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. Ann Fam Med 3: 60-63.
27. Gentleman RCV, Huber W, Irizarry R, Dudoit S, eds (2005) Bioinformatics and Computational Biology Solutions Using R and Bioconductor: Statistics for Biology and Health. 473 p.
28. Virella G, Carter RE, Saad A, Crosswell EG, Game BA, et al. (2008) Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy. Clin Immunol 127: 394-400.
29. Mirzaei H, Baena B, Barbas C, Regnier F (2008) Identification of oxidized proteins in rat plasma using avidin chromatography and tandem mass spectrometry. Proteomics 8: 1516-1527.
30. Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30.
31. Duchateau PN, Pullinger CR, Orellana RE, Kunitake ST, Naya-Vigne J, et al. (1997) Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 272: 25576-25582.
32. Getz GS, Reardon CA (2004) Paraoxonase, a cardioprotective enzyme: continuing issues. Curr Opin Lipidol 15: 261-267.
33. Heller M, Stalder D, Schlappritzi E, Hayn G, Matter U, et al. (2005) Mass spectrometry-based analytical tools for the molecular protein characterization of human plasma lipoproteins. Proteomics 5: 2619-2630.
34. Karlsson H, Leanderson P, Tagesson C, Lindahl M (2005) Lipoproteomics II: mapping of proteins in high-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 5: 1431-1445.
35. Kotite L, Zhang LH, Yu Z, Burlingame AL, Havel RJ (2003) Human apoC-IV: isolation, characterization, and immunochemical quantification in plasma and plasma lipoproteins. J Lipid Res 44: 1387-1394.
36. Kunitake ST, Carilli CT, Lau K, Protter AA, Naya-Vigne J, et al. (1994) Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. Biochemistry 33: 1988-1993.
37. McVicar JP, Kunitake ST, Hamilton RL, Kane JP (1984) Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I. Proc Natl Acad Sci U S A 81: 1356-1360.
38. Sprecher DL, Taam L, Gregg RE, Fojo SS, Wilson DM, et al. (1988) Identification of an apoC-II variant (apoC-IIBethesda) in a kindred with apoC-II deficiency and type 1 hyperlipoproteinemia. J Lipid Res 29: 273-278.
39. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC (2006) Proteomic analysis of high-density lipoprotein. Proteomics 6: 721-730.
40. Xu N, Dahlback B (1999) A novel human apolipoprotein (apoM). J Biol Chem 274: 31286-31290.
41. Zhang LH, Kotite L, Havel RJ (1996) Identification, characterization, cloning, and expression of apolipoprotein C-IV, a novel sialoglycoprotein of rabbit plasma lipoproteins. J Biol Chem 271: 1776-1783.
42. O'Brien PJ, Alborn WE, Sloan JH, Ulmer M, Boodhoo A, et al. (2005) The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51: 351-359.
43. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. (2004) The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45: 993-1007.
44. Whaley K, Schwaeble W (1997) Complement and complement deficiencies. Semin Liver Dis 17: 297-310.
45. Pascual M, French LE (1995) Complement in human diseases: looking towards the 21st century. Immunol Today 16: 58-61.
46. Ostergaard J, Hansen TK, Thiel S, Flyvbjerg A (2005) Complement activation and diabetic vascular complications. Clin Chim Acta 361: 10-19.
47. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54: 570-575.
48. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117: 746-756.
49. Syvanne M, Rosseneu M, Labeur C, Hilden H, Taskinen MR (1994) Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: a preliminary report. Atherosclerosis 105: 25-34.
50. Patrick L, Uzick M (2001) Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature. Altern Med Rev 6: 248-271.
51. Chen X, Tian H, Liu R (2004) Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients. Diabetes Res Clin Pract 66: 41-47.
52. Rothem L, Hartman C, Dahan A, Lachter J, Eliakim R, et al. (2007) Paraoxonases are associated with intestinal inflammatory diseases and intracellularly localized to the endoplasmic reticulum. Free Radic Biol Med 43: 730-739.
53. Mackness B, Hine D, McElduff P, Mackness M (2006) High C-reactive protein and low paraoxonase1 in diabetes as risk factors for coronary heart disease. Atherosclerosis 186: 396-401.
54. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, et al. (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 163: 93-99.
55. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, et al. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51: 1596-1600.
56. Pickup JC, Mattock MB, Chusney GD, Burt D (1997) NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40: 1286-1292.
57. McMillan DE (1989) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38: 1042-1046.
58. Kim CH, Park JY, Kim JY, Choi CS, Kim YI, et al. (2002) Elevated serum ceruloplasmin levels in subjects with metabolic syndrome: a population-based study. Metabolism 51: 838-842.
59. Barraviera B (1994) Acute-phase response in snakebite. Rev Inst Med Trop Sao Paulo 36: 479.
60. Kaysen GA (2001) The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12: 1549-1557.
61. Hansen TK, Tarnow L, Thiel S, Steffensen R, Stehouwer CD, et al. (2004) Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 53: 1570-1576.
62. Rosen BS, Cook KS, Yaglom J, Groves DL, Volanakis JE, et al. (1989) Adipsin and complement factor D activity: an immune-related defect in obesity. Science 244: 1483-1487.
63. Takahashi M, Mori S, Shigeta S, Fujita T (2007) Role of MBL-associated serine protease (MASP) on activation of the lectin complement pathway. Adv Exp Med Biol 598: 93-104.
64. Hansen TK (2005) Mannose-binding lectin (MBL) and vascular complications in diabetes. Horm Metab Res 37 Suppl 1: 95-98.
65. Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, et al. (1997) A second serine protease associated with mannan-binding lectin that activates complement. Nature 386: 506-510.
66. Vorup-Jensen T, Jensenius JC, Thiel S (1998) MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway. Immunobiology 199: 348-357.
67. Hansen TK, Gall MA, Tarnow L, Thiel S, Stehouwer CD, et al. (2006) Mannose-binding lectin and mortality in type 2 diabetes. Arch Intern Med 166: 2007-2013.